NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

Eldstein 全球市場(2016-2027):市場預測(按用途/最終用戶)/行業分析/區域展望/市場份額

Erdosteine Market Size By Application, By End-Use, Industry Analysis, Regional Outlook, Competitive Market Share & Forecast, 2016 - 2027

出版商 Global Market Insights Inc. 商品編碼 1007694
出版日期 內容資訊 英文 130 Pages
商品交期: 2-3個工作天內
價格
Eldstein 全球市場(2016-2027):市場預測(按用途/最終用戶)/行業分析/區域展望/市場份額 Erdosteine Market Size By Application, By End-Use, Industry Analysis, Regional Outlook, Competitive Market Share & Forecast, 2016 - 2027
出版日期: 2021年05月22日內容資訊: 英文 130 Pages
簡介

由於慢性病的增加和對臨床開發的日益重視,預計到 2027 年厄多司坦市場將顯著增長。

從應用來看,2020 年乾咳、特發性肺纖維化 (IPF) 和哮喘等其他領域的市場份額將超過 8%。

本報告探索了全球 Eldostain 市場,定義和概述了市場,分析了冠狀病毒病 (COVID-19) 和其他市場影響因素、法律環境、技術和創新。它總結了可持續性/專利趨勢、市場規模趨勢/預測,按各種類別細分,例如應用程序/最終用戶/地區/主要國家/地區、競爭環境和主要公司的簡介。

第一章調查方法/範圍

第 2 章執行摘要

第三章產業分析

  • 行業分類
  • COVID-19 的影響
  • 產業生態系統
  • 監管狀態
  • 技術情況
  • 成本結構分析
  • API 生產中使用的成分
  • 原材料分析 □ COVID-19 的影響
  • 價格分析 □ COVID-19 的影響
  • 行業影響因素
    • 增長因素
    • 潛在風險和挑戰
  • 增長潛力
  • 波特分析
  • 競爭形勢
  • PESTEL 分析
  • 其他祛痰藥市場概覽
  • 厄多司坦終產物的配製
  • 創新/可持續發展
  • 專利情況
  • COVID-19 的影響:最終用戶

第 4 章市場分析/預測:按應用

  • 支氣管炎
  • 慢性阻塞性肺疾病 (COPD)
  • 鼻咽炎
  • 其他

第 5 章市場分析/預測:按最終用戶

  • 製藥
  • 合同製造公司 (CMO)
  • 研究

第 6 章市場分析/預測:按地區/主要國家

  • 拉丁美洲
  • 中東/非洲

第 7 章公司簡介

  • Recipharm AB
  • Taj Pharmaceuticals Limited
  • Wuhan Hezhong Bio-Chemical Manufacture Co., Ltd.
  • Delta Finochem Pvt. Ltd.
  • Alitair Pharmaceuticals, Inc.
  • Salvavidas Pharmaceutical Private Limited
  • Zhejiang Kangle Pharmaceutical Co., Ltd.
  • Wuhan Yuancheng Pharmaceutical
  • Hanmi Pharmaceuticals Co., Ltd.
  • Shandong Luoxin Pharmaceutical
  • Asmoh Laboratories Ltd.
  • Hikma Pharmaceuticals
  • Jigs Chemical
目錄
Product Code: 3371

The erdosteine market is expected to witness substantial growth by 2027 owing to the rising incidences of chronic illnesses and rising focus on clinical development in the field.

Erdosteine is a commonly used mucoactive agent for treating several respiratory diseases. It is specifically used where the overlap of bacterial infection is more recurrent. The drug has also been approved for acute and chronic pulmonary diseases treatment.

It is a part of the thiol-based family of drugs, which possesses potentially significant anti-inflammatory and antioxidant properties. This class of drugs also demonstrates antibacterial activity against various medically prominent bacterial species.

Moreover, research has shown that erdosteine can prevent or reduce lung tissue damage resulting from oxidative stress.

The RESTORE study investigated the effects of a thiol-based drug in chronic obstructive pulmonary disease (COPD) frequent exacerbators. The study found that erdosteine could significantly lower the risk of acute exacerbations of COPD (AECOPDs). It also demonstrated that the drug shortened their course and reduced the need for hospitalization due to COPD.

The study concluded that integrating erdosteine into the usual COPD maintenance therapy reduced the frequency of mild exacerbations and shortened the duration of all exacerbations in patients diagnosed with moderate COPD and a medical history of exacerbations.

After the COVID-19 outbreak, the pharmaceutical industry collectively focused their efforts on identifying treatment methods and finding a cure for the infection.

In October 2020, leading pharmaceutical firm Recipharm announced that it had successfully concluded the research study exploring the use of erdosteine as an add-on when treating COVID-19 infected patients. The company stated that its proprietary molecule had tested positive as part of the COVID-19 treatment.

The clinical study saw the participation of 20 patients infected by the coronavirus experiencing severe respiratory failure. These patients were hospitalized in one of the largest COVID-19 centers in Milan, Lombardy. Lombardy was one of the worst hit regions in Italy during the pandemic.

Recipharm's study was the first to examine health-related quality of life parameters (HRQoL) details in patients affected by the COVID-19 infection.

The research conducted by the company found that patients who were administered erdosteine after they were discharged from the hospital exhibited significant improvement in dyspnea and HRQoL.

For comprehensive assessment, the erdosteine market has been segmented based on application, end-use, and region.

In terms of application, the market has further been segmented into bronchitis, COPD, nasopharyngitis, and others.

In 2020, the others application segment accounted for a share of over 8% in the erdosteine market. Other applications include dry cough, idiopathic pulmonary fibrosis (IPF), and asthma.

In the regional landscape, the Middle East & Africa erdosteine market is expected to witness significant growth in the coming years to garner over 4% gains by 2027 owing to the surging incidents of chronic illnesses across the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Methodology
  • 1.2 Market definitions
  • 1.3 Market estimation & forecast parameters
  • 1.4 Data Sources
    • 1.4.1 Primary
    • 1.4.2 Secondary
      • 1.4.2.1 Paid Sources
      • 1.4.2.2 Public Sources

Chapter 2 Executive Summary

  • 2.1 Erdosteine (API) industry 360 degree synopsis, 2021 - 2027
    • 2.1.1 Business Trends
    • 2.1.2 Regional trends
    • 2.1.3 Application trends
    • 2.1.4 End-use trends

Chapter 3 Erdosteine (API) Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Impact of COVID-19 on the global economy
  • 3.3 Industry ecosystem analysis
    • 3.3.1 Vendor matrix
    • 3.3.2 Distribution channel analysis
      • 3.3.2.1 Distributors/ Suppliers
      • 3.3.2.2 Contract Manufacturing
    • 3.3.3 Impact of COVID-19 on industry value chain
  • 3.4 Regulatory landscape
    • 3.4.1 U.S.
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
      • 3.4.3.1 Japan
      • 3.4.3.2 Australia
      • 3.4.3.3 India
  • 3.5 Technology Landscape
    • 3.5.1 Erdosteine synthesis
  • 3.6 Cost structure analysis, 2020
    • 3.6.1 Standard operating cost
    • 3.6.2 Raw material cost
    • 3.6.3 Labor cost
  • 3.7 Component used in API manufacturing
  • 3.8 Raw material analysis, Impact of COVID-19 on supply
    • 3.8.1 Thioglycolic acid
    • 3.8.2 Chloroacetyl chloride
    • 3.8.3 Isopropyl Alcohol
    • 3.8.4 HCL
    • 3.8.5 Methylene Dichloride
  • 3.9 Impact of COVID-19 on Pricing analysis
  • 3.10 Industry impact forces
    • 3.10.1 Growth drivers
      • 3.10.1.1 North America: Growing trends towards cigarette smoking and exposure to tobacco smoke leading to increase in COPD
      • 3.10.1.2 Europe: Exposure to polluted air quality leading to development of serious medical conditions like bronchitis
      • 3.10.1.3 Asia Pacific: Pharmaceutical market expansion
    • 3.10.2 Industry pitfalls & challenges
      • 3.10.2.1 Limitation of the drug with certain medical condition
  • 3.11 Growth potential analysis, 2020
    • 3.11.1 Emerging business model
      • 3.11.1.1 New product launch
      • 3.11.1.2 Collaboration/ Partnership
      • 3.11.1.3 Acquisition
  • 3.12 Porter's analysis
  • 3.13 Competitive landscape, 2020
    • 3.13.1 Company market share analysis, 2020
    • 3.13.2 Strategy dashboard
    • 3.13.3 Production capacity by company
    • 3.13.4 Production capacity by region
    • 3.13.5 Impact of COVID-19 on consumer buying behavior
  • 3.14 PESTEL analysis
  • 3.15 Other expectorant market overview
  • 3.16 Overview of final product formulation for erdosteine
  • 3.17 Innovation & sustainability
  • 3.18 Patent landscape
  • 3.19 Impact of COVID-19 on erdosteine demand by end-use
    • 3.19.1 Pharmaceutical
    • 3.19.2 CMOs
    • 3.19.3 Research Institutes

Chapter 4 Erdosteine (API) Market, By Application

  • 4.1 Key application trends
  • 4.2 Bronchitis
    • 4.2.1 Global erdosteine (API) market from bronchitis, 2016 - 2027, (Tons) (USD Million)
    • 4.2.2 Global erdosteine (API) market from bronchitis, by region, 2016 - 2027, (Tons) (USD Million)
  • 4.3 Chronic obstructive pulmonary disease (COPD)
    • 4.3.1 Global erdosteine (API) market from COPD, 2016 - 2027, (Tons) (USD Million)
    • 4.3.2 Global erdosteine (API) market from COPD, by region, 2016 - 2027, (Tons) (USD Million)
  • 4.4 Nasopharyngitis
    • 4.4.1 Global erdosteine (API) market from nasopharyngitis, 2016 - 2027, (Tons) (USD Million)
    • 4.4.2 Global erdosteine (API) market from nasopharyngitis, by region, 2016 - 2027, (Tons) (USD Million)
  • 4.5 Others
    • 4.5.1 Global erdosteine (API) market from other application, 2016 - 2027, (Tons) (USD Million)
    • 4.5.2 Global erdosteine (API) market from other application, by region, 2016 - 2027, (Tons) (USD Million)

Chapter 5 Erdosteine (API) Market, By End-Use

  • 5.1 Key end-use trends
  • 5.2 Pharmaceutical
    • 5.2.1 Global erdosteine (API) market from pharmaceutical, 2016 - 2027, (Tons) (USD Million)
    • 5.2.2 Global erdosteine (API) market from pharmaceutical, by region, 2016 - 2027, (Tons) (USD Million)
  • 5.3 Contract manufacturing companies (CMO's)
    • 5.3.1 Global erdosteine (API) market from Contract manufacturing companies, 2016 - 2027, (Tons) (USD Million)
    • 5.3.2 Global erdosteine (API) market from CMOs, by region, 2016 - 2027, (Tons) (USD Million)
  • 5.4 Research Institute
    • 5.4.1 Global erdosteine (API) market from research institute, 2016 - 2027, (Tons) (USD Million)
    • 5.4.2 Global erdosteine (API) market from research institute, by region, 2016 - 2027, (Tons) (USD Million)

Chapter 6 Erdosteine (API) Market, By Region

  • 6.1 Key regional trends
  • 6.2 Latin America (LATAM)
    • 6.2.1 LATAM erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
    • 6.2.2 LATAM erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
    • 6.2.3 LATAM erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
    • 6.2.4 Brazil
      • 6.2.4.1 Brazil erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
      • 6.2.4.2 Brazil erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
      • 6.2.4.3 Brazil erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
  • 6.3 Middle East & Africa (MEA)
    • 6.3.1 MEA erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
    • 6.3.2 MEA erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
    • 6.3.3 MEA erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
    • 6.3.4 Saudi Arabia
      • 6.3.4.1 Saudi Arabia erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
      • 6.3.4.2 Saudi Arabia erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
      • 6.3.4.3 Saudi Arabia erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
    • 6.3.5 South Africa
      • 6.3.5.1 South Africa erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
      • 6.3.5.2 South Africa erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
      • 6.3.5.3 South Africa erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)
    • 6.3.6 UAE
      • 6.3.6.1 UAE erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
      • 6.3.6.2 UAE erdosteine (API) market, by application, 2016 - 2027, (Tons) (USD Million)
      • 6.3.6.3 UAE erdosteine (API) market, by end-use, 2016 - 2027, (Tons) (USD Million)

Chapter 7 Company Profiles

  • 7.1 Recipharm AB
    • 7.1.1 Business Overview
    • 7.1.2 Financial Data
    • 7.1.3 Product Landscape
    • 7.1.4 SWOT Analysis
    • 7.1.5 Strategic Outlook
  • 7.2 Taj Pharmaceuticals Limited
    • 7.2.1 Business Overview
    • 7.2.2 Financial Data
    • 7.2.3 Product Landscape
    • 7.2.4 SWOT Analysis
  • 7.3 Wuhan Hezhong Bio-Chemical Manufacture Co., Ltd.
    • 7.3.1 Business Overview
    • 7.3.2 Financial Data
    • 7.3.3 Product Landscape
    • 7.3.4 SWOT Analysis
  • 7.4 Delta Finochem Pvt. Ltd.
    • 7.4.1 Business Overview
    • 7.4.2 Financial Data
    • 7.4.3 Product Landscape
    • 7.4.4 SWOT Analysis
  • 7.5 Alitair Pharmaceuticals, Inc.
    • 7.5.1 Business Overview
    • 7.5.2 Financial Data
    • 7.5.3 Product Landscape
    • 7.5.4 SWOT Analysis
  • 7.6 Salvavidas Pharmaceutical Private Limited
    • 7.6.1 Business Overview
    • 7.6.2 Financial Data
    • 7.6.3 Product Landscape
    • 7.6.4 SWOT Analysis
  • 7.7 Zhejiang Kangle Pharmaceutical Co., Ltd.
    • 7.7.1 Business Overview
    • 7.7.2 Financial Data
    • 7.7.3 Product Landscape
    • 7.7.4 SWOT Analysis
  • 7.8 Wuhan Yuancheng Pharmaceutical
    • 7.8.1 Business Overview
    • 7.8.2 Financial Data
    • 7.8.3 Product Landscape
    • 7.8.4 SWOT Analysis
  • 7.9 Hanmi Pharmaceuticals Co., Ltd.
    • 7.9.1 Business Overview
    • 7.9.2 Financial Data
    • 7.9.3 Product Landscape
    • 7.9.4 SWOT Analysis
  • 7.10 Shandong Luoxin Pharmaceutical
    • 7.10.1 Business Overview
    • 7.10.2 Financial Data
    • 7.10.3 Product Landscape
    • 7.10.4 SWOT Analysis
  • 7.11 Asmoh Laboratories Ltd.
    • 7.11.1 Business Overview
    • 7.11.2 Financial Data
    • 7.11.3 Product Landscape
    • 7.11.4 SWOT Analysis
  • 7.12 Hikma Pharmaceuticals
    • 7.12.1 Business Overview
    • 7.12.2 Financial Data
    • 7.12.3 Product Landscape
    • 7.12.4 SWOT Analysis
  • 7.13 Jigs Chemical
    • 7.13.1 Business Overview
    • 7.13.2 Financial Data
    • 7.13.3 Product Landscape
    • 7.13.4 SWOT Analysis

Data Tables

  • TABLE 1 Erdosteine (API) industry 360 degree synopsis, 2021 - 2027
  • TABLE 2 Global erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
  • TABLE 3 Global erdosteine (API) market volume, by region, 2013-2024 (Tons)
  • TABLE 4 Global erdosteine (API) market revenue, by region, 2013-2024 (USD Million)
  • TABLE 5 Global erdosteine (API) market volume, by application, 2016 - 2027, (Tons)
  • TABLE 6 Global erdosteine (API) market revenue, by application, 2016 - 2027, (USD Million)
  • TABLE 7 Global erdosteine (API) market volume, by end-use, 2016 - 2027 (Tons)
  • TABLE 8 Global erdosteine (API) market revenue, by end-use, 2016 - 2027 (USD Million)
  • TABLE 9 Vendor matrix
  • TABLE 10 Erdosteine (API) distribution channel analysis
  • TABLE 11 Operating cost distribution
  • TABLE 12 Industry impact forces
  • TABLE 13 Global erdosteine (API) market from bronchitis, 2016 - 2027, (Tons) (USD Million)
  • TABLE 14 Global erdosteine (API) market volume from bronchitis, by region, 2016 - 2027, (Tons)
  • TABLE 15 Global erdosteine (API) market revenue from bronchitis, by region, 2016 - 2027, (USD Million)
  • TABLE 16 Global erdosteine (API) market from COPD, 2016 - 2027, (Tons) (USD Million)
  • TABLE 17 Global erdosteine (API) market volume from COPD, by region, 2016 - 2027, (Tons)
  • TABLE 18 Global erdosteine (API) market revenue from COPD, by region, 2016 - 2027, (USD Million)
  • TABLE 19 Global erdosteine (API) market from nasopharyngitis, 2016 - 2027, (Tons) (USD Million)
  • TABLE 20 Global erdosteine (API) market volume from nasopharyngitis, by region, 2016 - 2027, (Tons)
  • TABLE 21 Global erdosteine (API) market revenue from nasopharyngitis, by region, 2016 - 2027, (USD Million)
  • TABLE 22 Global erdosteine (API) market from other application, 2016 - 2027, (Tons) (USD Million)
  • TABLE 23 Global erdosteine (API) market volume from other application, by region, 2016 - 2027, (Tons)
  • TABLE 24 Global erdosteine (API) market revenue from other application, by region, 2016 - 2027, (USD Million)
  • TABLE 25 Global erdosteine (API) market from pharmaceutical, 2016 - 2027, (Tons) (USD Million)
  • TABLE 26 Global erdosteine (API) market volume from pharmaceutical, by region, 2016 - 2027, (Tons)
  • TABLE 27 Global erdosteine (API) market revenue from pharmaceutical, by region, 2016 - 2027, (USD Million)
  • TABLE 28 Global erdosteine (API) market from CMOs, 2016 - 2027, (Tons) (USD Million)
  • TABLE 29 Global erdosteine (API) market volume from CMOs, by region, 2016 - 2027, (Tons)
  • TABLE 30 Global erdosteine (API) market revenue from CMOs, by region, 2016 - 2027, (USD Million)
  • TABLE 31 Global erdosteine (API) market from research institute, 2016 - 2027, (Tons) (USD Million)
  • TABLE 32 Global erdosteine (API) market volume from research institute, by region, 2016 - 2027, (Tons)
  • TABLE 33 Global erdosteine (API) market revenue from research institute, by region, 2016 - 2027, (USD Million)
  • TABLE 34 LATAM erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
  • TABLE 35 LATAM erdosteine (API) market volume, by application, 2016 - 2027, (Tons)
  • TABLE 36 LATAM erdosteine (API) market revenue, by application, 2016 - 2027, (USD Million)
  • TABLE 37 LATAM erdosteine (API) market volume, by end-use, 2016 - 2027, (Tons)
  • TABLE 38 LATAM erdosteine (API) market revenue, by end-use, 2016 - 2027, (USD Million)
  • TABLE 39 Brazil erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
  • TABLE 40 Brazil erdosteine (API) market volume, by application, 2016 - 2027, (Tons)
  • TABLE 41 Brazil erdosteine (API) market revenue, by application, 2016 - 2027, (USD Million)
  • TABLE 42 Brazil erdosteine (API) market volume, by end-use, 2016 - 2027, (Tons)
  • TABLE 43 Brazil erdosteine (API) market revenue, by end-use, 2016 - 2027, (USD Million)
  • TABLE 44 MEA erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
  • TABLE 45 MEA erdosteine (API) market volume, by application, 2016 - 2027, (Tons)
  • TABLE 46 MEA erdosteine (API) market revenue, by application, 2016 - 2027, (USD Million)
  • TABLE 47 MEA erdosteine (API) market volume, by end-use, 2016 - 2027, (Tons)
  • TABLE 48 MEA erdosteine (API) market revenue, by end-use, 2016 - 2027, (USD Million)
  • TABLE 49 Saudi Arabia erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
  • TABLE 50 Saudi Arabia erdosteine (API) market volume, by application, 2016 - 2027, (Tons)
  • TABLE 51 Saudi Arabia erdosteine (API) market revenue, by application, 2016 - 2027, (USD Million)
  • TABLE 52 Saudi Arabia erdosteine (API) market volume, by end-use, 2016 - 2027, (Tons)
  • TABLE 53 Saudi Arabia erdosteine (API) market revenue, by end-use, 2016 - 2027, (USD Million)
  • TABLE 54 South Africa erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
  • TABLE 55 South Africa erdosteine (API) market volume, by application, 2016 - 2027, (Tons)
  • TABLE 56 South Africa erdosteine (API) market revenue, by application, 2016 - 2027, (USD Million)
  • TABLE 57 South Africa erdosteine (API) market volume, by end-use, 2016 - 2027, (Tons)
  • TABLE 58 South Africa erdosteine (API) market revenue, by end-use, 2016 - 2027, (USD Million)
  • TABLE 59 UAE erdosteine (API) market, 2016 - 2027, (Tons) (USD Million)
  • TABLE 60 UAE erdosteine (API) market volume, by application, 2016 - 2027, (Tons)
  • TABLE 61 UAE erdosteine (API) market revenue, by application, 2016 - 2027, (USD Million)
  • TABLE 62 UAE erdosteine (API) market volume, by end-use, 2016 - 2027, (Tons)
  • TABLE 63 UAE erdosteine (API) market revenue, by end-use, 2016 - 2027, (USD Million)

Charts & Figures

  • FIG. 1 Air pollution sources, 2017, (% share)
  • FIG. 2 Lung disease contributing to estimated current annual deaths, 2018, (% share)
  • FIG. 3 Chronic Obstructive pulmonary disease 35 years and over, 2017, (% share)
  • FIG. 4 Chronic Obstructive pulmonary disease 35 years and over, 2017, ()
  • FIG. 5 Industry segmentation
  • FIG. 6 Industry ecosystem analysis
  • FIG. 7 Value chain of generic pharmaceuticals
  • FIG. 8 Erdosteine synthesis
  • FIG. 9 New Microfluidic Technique & Continuous Process Method
  • FIG. 10 Cost structure of API manufacturing, 2020, (% share)
  • FIG. 11 Raw material break-up for erdosteine, 2020, (% share)
  • FIG. 12 Reactor Types
  • FIG. 13 Thioglycolic acid market estimates & forecast, 2016 - 2027, (Kilo Ton)
  • FIG. 14 Chloroacetyl chloride market estimates & forecast, 2016 - 2027, (USD Million)
  • FIG. 15 Isopropyl alcohol market estimates & forecast, 2016 - 2027, (USD Million)
  • FIG. 16 Hydrochloric acid market estimates & forecast, 2016 - 2027, (USD Billion)
  • FIG. 17 Methylene dichloride market estimates & forecast, 2016 - 2027, (USD Million)
  • FIG. 18 Erdosteine (API) ex-factory price, 2016-2027, (USD/kilo)
  • FIG. 19 North America current cigarette smoking data, by age group, 2017, (% share)
  • FIG. 20 Tobacco products among high school students, by type, 2018, (% share)
  • FIG. 21 Asia Pacific pharmaceutical market, 2013-2024, (USD Billion)
  • FIG. 22 India primary cause of respiratory diseases, (% share), 2017
  • FIG. 23 Growth potential analysis, 2020
  • FIG. 24 Porter's analysis
  • FIG. 25 Erdosteine (API) company market share analysis, 2020
  • FIG. 26 Porter's analysis
  • FIG. 27 SWOT Analysis, Recipharm AB
  • FIG. 28 SWOT Analysis, Taj Pharmaceuticals
  • FIG. 29 SWOT Analysis, Wuhan Hezhong Bio-Chemical Manufacture Co., Ltd
  • FIG. 30 SWOT Analysis, Delta Finochem Pvt. Ltd
  • FIG. 31 SWOT Analysis, Alitair Pharmaceuticals Inc.
  • FIG. 32 SWOT Analysis, Salvavidas Pharmaceutical Private Limited
  • FIG. 33 SWOT Analysis, Zhejiang Kangle Pharmaceuticals Co., Ltd.
  • FIG. 34 SWOT Analysis, Wuhan Yuancheng Pharmaceutical
  • FIG. 35 SWOT Analysis, Hanmi Pharmaceuticals Co., Ltd.
  • FIG. 36 SWOT Analysis, Shandong Luoxin Pharmaceutical
  • FIG. 37 SWOT Analysis, Asmoh Laboratories Ltd
  • FIG. 38 SWOT Analysis, Hikma Pharmaceuticals
  • FIG. 39 SWOT Analysis, Jigs Chemicals